Market Overview

UPDATE: Webush Upgrades Ironwood Pharmaceuticals on Completed Financing


In a report published on Thursday, Wedbush analyst Gregory R. Wade Upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Underperform to Neutral and maintained a price target of $12 on the company on recently completed financing and Linzess script metrics.

In the report, Wedbush stated, "While IRWD shares could benefit in the short term from the upwardly revised Street LINZESS estimates, our medium-term outlook remains cautious. We believe even potentially improving LINZESS growth metrics are unlikely to see the shares appreciate from these levels, given the company's ~$1.4billion enterprise value."

Ironwood Pharmaceuticals closed on Wednesday at $13.07.

Latest Ratings for IRWD

Feb 2021Morgan StanleyMaintainsEqual-Weight
Feb 2021Morgan StanleyMaintainsEqual-Weight
Nov 2020Credit SuisseMaintainsNeutral

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings


Related Articles (IRWD)

View Comments and Join the Discussion!

Posted-In: Gregory R. Wade Ironwood Pharmaceuticals NASDAQ WedbushAnalyst Color Upgrades Analyst Ratings

Latest Ratings

TDOCDA DavidsonMaintains275.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at